• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清HE4、CA125、CA72-4及ROMA指数在卵巢癌诊断及术后复发预测中的临床价值

Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.

作者信息

Wang Qin, Wu Yuanyuan, Zhang Hao, Yang Kai, Tong Yang, Chen Liwen, Zhou Qiang, Guan Shihe

出版信息

Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.181030.

DOI:10.7754/Clin.Lab.2018.181030
PMID:30969083
Abstract

BACKGROUND

Ovarian cancer is one of the most common cancers among women. With cancer, early detection is paramount to saving lives. However, early detection of ovarian cancer has been fraught with difficulty. The diagnostic performance of HE4, CA125, ROMA index, and CA72-4 was evaluated for ovarian cancer.

METHODS

This was a diagnostic study enrolling 97 patients with pelvic masses who had been scheduled for surgery and 33 healthy women. Serum levels of tumor markers, including human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), and carbohydrate antigen 72-4 (CA72-4) were detected in each patient and analyzed using the risk of ovarian malignancy algorithm (ROMA) index for sensitivity, specificity, positive predictive values, negative predictive values, and accuracy. ROC curve analysis was conducted to compare the diagnostic performances of serum HE4, CA125, CA72-4, and ROMA index in ovarian cancer. The dynamic changes of these biomarkers were analyzed in patients with ovarian cancer after operation.

RESULTS

HE4 had the best specificity, CA72-4 had the lowest sensitivity, and ROMA index had the best diagnostic efficiency among these biomarkers for diagnosis of ovarian cancer. CA125 had better specificity in the post-menopausal group than in non-menopausal group. The kinetic changes of HE4, CA125, and ROMA index in patients with ovarian cancer were consistent with the remission and recurrence of the disease.

CONCLUSIONS

HE4 and ROMA index which reference intervals are established according to the menopausal status have important clinical significance in the diagnosis of ovarian cancer. Regular detection of serum HE4, CA125, and ROMA index can help predict postoperative recurrence of ovarian cancer.

摘要

背景

卵巢癌是女性中最常见的癌症之一。对于癌症而言,早期检测对于挽救生命至关重要。然而,卵巢癌的早期检测一直充满困难。对人附睾蛋白4(HE4)、癌抗原125(CA125)、风险卵巢恶性肿瘤算法(ROMA)指数和癌抗原72-4(CA72-4)在卵巢癌诊断中的性能进行了评估。

方法

这是一项诊断性研究,纳入了97例计划接受手术的盆腔肿块患者和33名健康女性。检测每位患者血清中的肿瘤标志物水平,包括人附睾蛋白4(HE4)、癌抗原125(CA125)和癌抗原72-4(CA72-4),并使用ROMA指数分析其敏感性、特异性、阳性预测值、阴性预测值和准确性。进行ROC曲线分析以比较血清HE4、CA125、CA72-4和ROMA指数在卵巢癌诊断中的性能。分析卵巢癌患者术后这些生物标志物的动态变化。

结果

在这些用于诊断卵巢癌的生物标志物中,HE4具有最佳特异性,CA72-4具有最低敏感性,ROMA指数具有最佳诊断效率。CA125在绝经后组中的特异性高于非绝经组。卵巢癌患者中HE4、CA125和ROMA指数的动态变化与疾病的缓解和复发一致。

结论

根据绝经状态建立参考区间的HE4和ROMA指数在卵巢癌诊断中具有重要临床意义。定期检测血清HE4、CA125和ROMA指数有助于预测卵巢癌术后复发。

相似文献

1
Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.血清HE4、CA125、CA72-4及ROMA指数在卵巢癌诊断及术后复发预测中的临床价值
Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.181030.
2
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.评估 HE4、CA125、卵巢恶性肿瘤风险算法(ROMA)和恶性肿瘤指数(RMI)在盆腔肿块患者中作为上皮性卵巢癌的诊断工具。
Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.
3
Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.CA125、人附睾蛋白 4 和 CA72-4 水平及卵巢恶性肿瘤风险算法值在韩国有和无子宫内膜异位症的卵巢肿瘤患者中的临床应用。
Ann Lab Med. 2020 Jan;40(1):40-47. doi: 10.3343/alm.2020.40.1.40.
4
HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.人附睾蛋白4、癌抗原125、恶性风险算法和恶性风险指数与复杂盆腔肿块——澳大利亚人群盆腔肿块术前评估中的前瞻性比较
Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363. Epub 2015 Jul 14.
5
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.HE4、CA125及卵巢恶性肿瘤风险算法在韩国女性卵巢癌预测中的比较
J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.
6
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4(HE4)和卵巢恶性肿瘤风险算法(ROMA)作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
7
Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.HE4、CA125 和 ROMA 算法在盆腔肿块女性中的比较:与病理结果的相关性。
Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.
8
Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.CA125、HE4 和 ROMA 指数在卵巢癌诊断中的比较。
Curr Probl Cancer. 2019 Apr;43(2):135-144. doi: 10.1016/j.currproblcancer.2018.06.001. Epub 2018 Jun 12.
9
Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.开发一种多标志物检测方法用于鉴别诊断良恶性盆腔包块。
Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.
10
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?ROMA(卵巢恶性肿瘤风险算法)用于评估有盆腔肿块表现的女性患上皮性卵巢癌的风险:它真的有用吗?
Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075. Epub 2011 Feb 3.

引用本文的文献

1
Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches.基于临床数据,运用机器学习方法对卵巢癌进行早期预测和风险分层。
J Gynecol Oncol. 2025 Jul;36(4):e53. doi: 10.3802/jgo.2025.36.e53. Epub 2024 Dec 17.
2
Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.评估卵巢癌患者选定免疫和分子参数测定的潜在诊断效用。
Diagnostics (Basel). 2023 May 12;13(10):1714. doi: 10.3390/diagnostics13101714.
3
Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers.
通过对代谢物、脂蛋白和炎症标志物进行定量血清核磁共振波谱分析,对卵巢交界性癌患者与高级别浆液性癌患者进行分层。
Front Mol Biosci. 2023 Apr 19;10:1158330. doi: 10.3389/fmolb.2023.1158330. eCollection 2023.
4
Mucins as Potential Biomarkers for Early Detection of Cancer.黏蛋白作为癌症早期检测的潜在生物标志物。
Cancers (Basel). 2023 Mar 7;15(6):1640. doi: 10.3390/cancers15061640.
5
Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.血清胃蛋白酶原和糖类抗原72-4(CA72-4)联合胃泌素-17(G-17)检测在早期胃癌筛查、诊断及评估中的应用
J Gastrointest Oncol. 2021 Jun;12(3):1042-1048. doi: 10.21037/jgo-21-254.
6
Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.异常甲基化特征可预测晚期高级别浆液性卵巢癌的化疗耐药性和不良预后。
Clin Epigenetics. 2021 Jul 21;13(1):141. doi: 10.1186/s13148-021-01133-2.
7
MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.MRPL15 是上皮性卵巢癌的一种新型预后生物标志物和治疗靶点。
Cancer Med. 2021 Jun;10(11):3655-3673. doi: 10.1002/cam4.3907. Epub 2021 May 2.
8
Role of biomarkers for early detection of ovarian cancer recurrence.生物标志物在卵巢癌复发早期检测中的作用。
Gland Surg. 2020 Aug;9(4):1102-1111. doi: 10.21037/gs-20-544.
9
Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.术前血清 HE4 和 CA125 水平预测晚期上皮性卵巢癌初次理想肿瘤细胞减灭术:初步模型研究。
J Ovarian Res. 2020 Feb 12;13(1):17. doi: 10.1186/s13048-020-0614-1.